1
|
Domschke C, Diel IJ, Englert S, Kalteisen S, Mayer L, Rom J, Heil J, Sohn C, Schuetz F. Prognostic value of disseminated tumor cells in the bone marrow of patients with operable primary breast cancer: a long-term follow-up study. Ann Surg Oncol 2012; 20:1865-71. [PMID: 23263703 DOI: 10.1245/s10434-012-2814-4] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2012] [Indexed: 11/18/2022]
Abstract
BACKGROUND Detection of disseminated tumor cells (DTC) in primary breast cancer (BC) patients' bone marrow (BM) seems to be a surrogate marker of tumor spread and an independent prognostic factor for disease-free and overall survival. METHODS Here we present the largest single-center cohort of patients (n = 1378) with the longest observation time (median 82.0 months). Immunocytochemical staining was performed using murine monoclonal antibody 2E11 with the avidin-biotin complex technique. RESULTS At primary surgery, 49 % of patients showed MUC-1 positive cells inside their BM. Patients without BM DTC had significantly more often T1-tumors (P = 0.007) with less often affected axillary lymph nodes (P < 0.001). We observed a significantly higher incidence of distant metastases in DTC positive patients (P < 0.001). This leads to a reduced disease-free survival (P < 0.0001). Furthermore, in DTC positive patients there was a higher mortality rate and, accordingly, a reduced overall survival (P < 0.0001). CONCLUSIONS Due to the presence of BM DTC, patients with a clinically poorer outcome can be identified at primary surgery. We therefore suggest that DTC analysis can be used as a prognostic factor and monitoring tool in clinical trials. Future study concepts relating to DTC should aim at identification of BC patients who may profit from adjuvant systemic therapy.
Collapse
|
2
|
Benoy IH, Elst H, Philips M, Wuyts H, Van Dam P, Scharpé S, Van Marck E, Vermeulen PB, Dirix LY. Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. Br J Cancer 2006; 94:672-80. [PMID: 16495933 PMCID: PMC2361203 DOI: 10.1038/sj.bjc.6602985] [Citation(s) in RCA: 126] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
This study assessed the ability of real-time reverse transcription–polymerase chain reaction (RT–PCR) analysis to detect disseminated epithelial cells (DEC) in peripheral blood (PB) and bone marrow (BM) of patients with breast cancer (BC). Detection of DEC in BM is an obvious choice in BC, but blood sampling is more convenient. The aim of this study was to evaluate whether the detection of DEC in either PB or BM predicts overall survival (OS). Peripheral blood and BM samples were collected from 148 patients with primary (stage M0, n=116/78%) and metastatic (stage M+, n=32/21%) BC before the initiation of any local or systemic treatment. Peripheral blood of healthy volunteers and BM of patients with a nonmalignant breast lesion or a haematological malignancy served as the control group. Disseminated epithelial cells was detected by measuring relative gene expression (RGE) for cytokeratin-19 (CK-19) and mammaglobin (MAM), using a quantitative RT–PCR detection method. The mean follow-up time was 786 days (+/− 487). Kaplan–Meier analysis was used for predicting OS. By taking the 95 percentile of the RGE of CK-19 (BM: 26.3 and PB: 58.7) of the control group as cutoff, elevated CK-19 expression was detected in 42 (28%) BM samples and in 22 (15%) PB samples. Mammaglobin expression was elevated in 20% (both PB and BM) of the patients with BC. There was a 68% (CK-19) and 75% (MAM) concordance between PB and BM samples when classifying the results as either positive or negative. Patients with an elevated CK-19 or MAM expression in the BM had a worse prognosis than patients without elevated expression levels (OS: log-rank test, P=0.0045 (CK-19) and P=0.025 (MAM)). For PB survival analysis, no statistical significant difference was observed between patients with or without elevated CK-19 or MAM expression (OS: log-rank test, P=0.551 (CK-19) and P=0.329 (MAM)). Separate analyses of the M0 and M+ patients revealed a marked difference in OS according to the BM CK-19 or MAM status in the M+ patient group, but in the M0 group, only MAM expression was a prognostic marker for OS. Disseminated epithelial cells, measured as elevated CK-19 or MAM mRNA expression, could be detected in both PB and BM of patients with BC. Only the presence of DEC in BM was highly predictive for OS. The occurrence of DEC in the BM is probably less time-dependent and may act as a filter for circulating BC cells. The use of either larger volumes of PB or performing an enrichment step for circulating tumour in blood cells might improve these results.
Collapse
Affiliation(s)
- I H Benoy
- Translational Cancer Research Group Antwerp, Department of Pathology University of Antwerp/University Hospital Antwerp, Edegem 2650, Belgium
- Translational Cancer Research Group Antwerp, Oncology Centre, General Hospital Sint-Augustinus, Oosterveldlaan 24, Wilrijk 2610, Belgium
| | - H Elst
- Translational Cancer Research Group Antwerp, Department of Pathology University of Antwerp/University Hospital Antwerp, Edegem 2650, Belgium
- Translational Cancer Research Group Antwerp, Oncology Centre, General Hospital Sint-Augustinus, Oosterveldlaan 24, Wilrijk 2610, Belgium
| | - M Philips
- Translational Cancer Research Group Antwerp, Department of Pathology University of Antwerp/University Hospital Antwerp, Edegem 2650, Belgium
- Translational Cancer Research Group Antwerp, Oncology Centre, General Hospital Sint-Augustinus, Oosterveldlaan 24, Wilrijk 2610, Belgium
| | - H Wuyts
- Translational Cancer Research Group Antwerp, Department of Pathology University of Antwerp/University Hospital Antwerp, Edegem 2650, Belgium
- Translational Cancer Research Group Antwerp, Oncology Centre, General Hospital Sint-Augustinus, Oosterveldlaan 24, Wilrijk 2610, Belgium
| | - P Van Dam
- Translational Cancer Research Group Antwerp, Department of Pathology University of Antwerp/University Hospital Antwerp, Edegem 2650, Belgium
- Translational Cancer Research Group Antwerp, Oncology Centre, General Hospital Sint-Augustinus, Oosterveldlaan 24, Wilrijk 2610, Belgium
| | - S Scharpé
- Medical Biochemistry, University of Antwerp, Wilrijk 2610, Belgium
| | - E Van Marck
- Translational Cancer Research Group Antwerp, Department of Pathology University of Antwerp/University Hospital Antwerp, Edegem 2650, Belgium
- Translational Cancer Research Group Antwerp, Oncology Centre, General Hospital Sint-Augustinus, Oosterveldlaan 24, Wilrijk 2610, Belgium
| | - P B Vermeulen
- Translational Cancer Research Group Antwerp, Department of Pathology University of Antwerp/University Hospital Antwerp, Edegem 2650, Belgium
- Translational Cancer Research Group Antwerp, Oncology Centre, General Hospital Sint-Augustinus, Oosterveldlaan 24, Wilrijk 2610, Belgium
| | - L Y Dirix
- Translational Cancer Research Group Antwerp, Department of Pathology University of Antwerp/University Hospital Antwerp, Edegem 2650, Belgium
- Translational Cancer Research Group Antwerp, Oncology Centre, General Hospital Sint-Augustinus, Oosterveldlaan 24, Wilrijk 2610, Belgium
- Translational Cancer Research Group Antwerp, Oncology Centre, General Hospital Sint-Augustinus, Oosterveldlaan 24, Wilrijk 2610, Belgium; E-mail: , www.tcrg.be
| |
Collapse
|
3
|
Dirix L, Van Dam P, Vermeulen P. Genomics and circulating tumor cells: promising tools for choosing and monitoring adjuvant therapy in patients with early breast cancer? Curr Opin Oncol 2005; 17:551-8. [PMID: 16224232 DOI: 10.1097/01.cco.0000183669.61767.81] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
PURPOSE OF REVIEW Gene expression profiling using a class discovery approach has consistently shown that breast cancer emerges as a group of different disease entities: the basal-like, the human epidermal growth factor receptor 2 type, the normal breast-like, and at least two different hormone receptor positive or luminal types. Initial reports have also suggested that certain expression patterns are associated with relapse. Current data on adjuvant therapy are only beginning to consider this biologic heterogeneity (estrogen receptor and human epidermal growth factor receptor 2 status). Similarly, the search for isolated tumor cells in blood or bone marrow has been regarded as another approach for defining prognosis and tailoring adjuvant therapies. The purpose of this review is to highlight the recent data emerging from both approaches as a means of assessing prognosis and tailoring therapy in patients with early breast cancer. RECENT FINDINGS The initial reports on prognosis assessment of breast cancer using the expression profile have been corroborated, but the differences between the actual genes selected for the different prognostic signatures remain difficult to explain. Others have introduced added signatures, such as those associated with proliferation or with wound healing, or selected subgroups on the basis of, for example, estrogen receptor level prior to class comparison. The data on the quantification of expression of a limited number of selected genes are promising for both prognosis and prediction. The segregation of histological grade 2 tumors into genetically defined grade 1 or 3 tumors and its associated prognostic significance is a critical observation. The standardization of methods for measuring isolated tumor cells in blood or bone marrow has resulted in validated data both on prognosis in early breast cancer and in the advanced setting. Methylation of circulating DNA might become another method for selecting patients for extended adjuvant regimens. SUMMARY The new molecular knowledge must be incorporated into prospective clinical studies in patients with early breast cancer. This is the challenge for the years to come.
Collapse
Affiliation(s)
- Luc Dirix
- Oncology Center, Algemeen Ziekenhuis Sint-Augustinus, Antwerp, Belgium.
| | | | | |
Collapse
|